PIXCLARA Drug Patent Profile
Which patents cover Pixclara, and when can generic versions of Pixclara launch?
Pixclara is a drug marketed by Telix and is included in one NDA.
The generic ingredient in PIXCLARA is floretyrosine f-18. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the floretyrosine f-18 profile page.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for PIXCLARA?
- What are the global sales for PIXCLARA?
- What is Average Wholesale Price for PIXCLARA?
Summary for PIXCLARA
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| What excipients (inactive ingredients) are in PIXCLARA? | PIXCLARA excipients list |
| DailyMed Link: | PIXCLARA at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for PIXCLARA
Generic Entry Date for PIXCLARA*:
Constraining patent/regulatory exclusivity:
NEW CHEMICAL ENTITY NDA:
Dosage:
SOLUTION;INTRAVENOUS |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
US Patents and Regulatory Information for PIXCLARA
PIXCLARA is protected by zero US patents and one FDA Regulatory Exclusivity.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of PIXCLARA is ⤷ Start Trial.
This potential generic entry date is based on NEW CHEMICAL ENTITY.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Telix | PIXCLARA | floretyrosine f-18 | SOLUTION;INTRAVENOUS | 218592-001 | Sep 11, 2026 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
